To date, no control cohort has been published comparing prediction to the real-life setting. This new score is now available online at .uk/mpn-multistage. Internal cross-validation showed concordances in 76% to 86% as well as good performance for absolute predictive accuracy. This score can predict overall survival (OS), event-free survival (EFS) and transformation-free survival (TFS) rates for each group. Grinfeld and colleagues analysed a cohort of 2 035 MPN patients and identified eight genomic subgroups of MPN by their clinical, biological and molecular characteristics (driver mutations and NGS analysis). The new MPN Genomic Calculator was published in October 2018. However, this score is not commonly used by physicians in their daily practice. The only prognostic scoring system for ET is the IPSET-Survival score.
Cytoreductive drugs should be reserved for older patients or those with a history of thrombosis.
3 Young patients are supposed to be treated by low-dose aspirin only. In MPN, according to next-generation sequencing (NGS) analyses, ASXL1, IDH1/2, EZH2, SRSF2, TET2 and TP53 are the most frequent additional mutations responsible for chemoresistance and transformation.
#GENOMIC HEALTH CALCULATOR DRIVER#
1, 2 ET is secondary to the acquisition of driver mutations such as JAK2V617F, CALR1/2 and MPLW515K/L. Patients are exposed to high risk of thrombotic/haemorrhagic complications and transformations into secondary myelofibrosis (SMF) or acute myeloid leukaemia (AML). The median age at diagnosis is between 50 and 60 years. Essential thrombocythaemia (ET) is the most common myeloproliferative neoplasm (MPN).
0 kommentar(er)
